FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

In times of market uncertainties, high-dividend yield stocks are ideal investment choices for their qualities like stable passive income, protection against inflation, and price appreciation. Thus, ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

A solid showing for HIV drugs sold by majority-owned ViiV Healthcare and speciality medicines like cancer therapies Zejula ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most ...